Skip to main content

Table 2 Number of PET–CTs in which ‘added value’ was detected compared to conventional imaging (MRI/CT) according to sarcoma subtype

From: Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma

Sarcoma pathological diagnosis Percentage of PET–CT with added value Number of PET–CT with added value over MRI/CT
Staging Restaging Treatment response
Undifferentiated pleomorphica 13.3% (22/166) 6 11 5
Angiosarcomab 9% (1/11) 1 0 0
Leiomyosarcoma 18% (30/166) 7 14 9
Rhabdomyosarcoma 24.6% (13/53) 3 2 8
Myxofibrosarcoma 26.7% (8/30) 0 5 3
Epithelioid sarcoma 13% (3/23) 1 2 0
Osteosarcoma 23.5% (23/98) 6 9 8
Clear cell sarcoma 12.5% (1/8) 1 0 0
Ewing sarcoma/DSRCT 27.5% (33/120) 7 12 14
Synovial sarcoma 13.6% (6/44) 3 2 1
De-differentiated liposarcoma 8.3% (3/36) 1 1 1
Solitary fibrous tumour 28% (7/25) 0 5 2
Chondrosarcoma grade 2/3 24.4% (11/45) 3 5 3
Myxoid/round cell liposarcoma 11.1% (4/36) 2 1 1
Alveolar soft part sarcoma 25% (1/4) 1 0 0
MPNST 41.6% (27/65) 14 9 4
Low grade soft tissue sarcoma 0% (0/17) 0 0 0
Chondrosarcoma grade 1 0% (0/10) 0 0 0
Total 21% (193/930) 56 78 59
  1. DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade
  2. aIncludes high grade ‘spindle cell sarcoma’
  3. bIncludes ‘high grade epitheloid haemangioendothelioma’